Samil Pharm (000520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Samil Pharm (000520) has a cash flow conversion efficiency ratio of 0.016x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.44 Billion ≈ $1.66 Million USD) by net assets (₩149.26 Billion ≈ $101.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Samil Pharm - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Samil Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Samil Pharm total liabilities for a breakdown of total debt and financial obligations.
Samil Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Samil Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sungdo Engineering & Construction Co. Ltd
KQ:037350
|
-0.036x |
|
Shaver Shop Group Ltd
AU:SSG
|
0.391x |
|
Reliance Industrial Infrastructure Limited
NSE:RIIL
|
-0.029x |
|
Diginex Limited Ordinary Shares
NASDAQ:DGNX
|
N/A |
|
NET Power Inc.
NYSE:NPWR
|
-0.052x |
|
Super Energy Corporation Public Company Limited
BK:SUPER-R
|
0.082x |
|
Haivision Systems Inc
TO:HAI
|
0.127x |
|
King Core Electronics Inc
TW:6155
|
0.045x |
Annual Cash Flow Conversion Efficiency for Samil Pharm (2012–2024)
The table below shows the annual cash flow conversion efficiency of Samil Pharm from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 000520 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩176.12 Billion ≈ $119.36 Million |
₩2.59 Billion ≈ $1.76 Million |
0.015x | -84.00% |
| 2023-12-31 | ₩127.83 Billion ≈ $86.63 Million |
₩11.75 Billion ≈ $7.96 Million |
0.092x | +178.32% |
| 2022-12-31 | ₩125.82 Billion ≈ $85.27 Million |
₩4.15 Billion ≈ $2.82 Million |
0.033x | +53.20% |
| 2021-12-31 | ₩65.75 Billion ≈ $44.56 Million |
₩1.42 Billion ≈ $960.19K |
0.022x | -82.38% |
| 2020-12-31 | ₩63.55 Billion ≈ $43.07 Million |
₩7.77 Billion ≈ $5.27 Million |
0.122x | -28.06% |
| 2019-12-31 | ₩62.27 Billion ≈ $42.20 Million |
₩10.59 Billion ≈ $7.18 Million |
0.170x | +463.81% |
| 2018-12-31 | ₩56.08 Billion ≈ $38.01 Million |
₩-2.62 Billion ≈ $-1.78 Million |
-0.047x | -163.08% |
| 2017-12-31 | ₩51.17 Billion ≈ $34.68 Million |
₩3.79 Billion ≈ $2.57 Million |
0.074x | -30.47% |
| 2016-12-31 | ₩52.87 Billion ≈ $35.83 Million |
₩5.63 Billion ≈ $3.82 Million |
0.107x | +98.58% |
| 2015-12-31 | ₩54.41 Billion ≈ $36.87 Million |
₩2.92 Billion ≈ $1.98 Million |
0.054x | +124.94% |
| 2014-12-31 | ₩55.42 Billion ≈ $37.55 Million |
₩-11.92 Billion ≈ $-8.08 Million |
-0.215x | -277.61% |
| 2013-12-31 | ₩70.03 Billion ≈ $47.46 Million |
₩-3.99 Billion ≈ $-2.70 Million |
-0.057x | -171.32% |
| 2012-12-31 | ₩62.87 Billion ≈ $42.61 Million |
₩5.02 Billion ≈ $3.40 Million |
0.080x | -- |
About Samil Pharm
Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inf… Read more